Home »
Academic Articles »
C »
Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review
Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review
Masroor Badshah
(Hudson Institute of Medical Research, Monash University, Clayton, VIC 3168, Australia)
Jibriil Ibrahim
(Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia)
Khaled A. Elnahriry
(Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, Riyadh 11533, Saudi Arabia)
Ralf Middendorff
(Institute of Anatomy and Cell Biology, Justus-Liebig-University, 35390 Giessen, Germany)
Michael Whittaker
(Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia)
Betty Exintaris
(Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia)
Journal: Biomedicines
•
• MDPI AG
• ISSN: 2227-9059
Abstract
Lower urinary tract symptoms (LUTSs) associated with benign prostatic disease and overactive bladder syndrome (OAB) substantially impair quality of life. This narrative review evaluates oxytocin receptor (OXTR) localisation, signalling, and contractile responses in prostate and bladder tissue, with anatomical and pharmacological context restricted to interpretation of these findings. Experimental receptor expression and antagonist responses provide mechanistic plausibility, but species differences, vasopressin receptor cross-reactivity, and inconsistent human tissue responses limit translation. Preclinical effects on tissue contractility and reproductive endpoints are distinguished from clinical urinary outcomes. OXTR antagonism remains investigational for LUTSs and OAB; clinical efficacy and safety require validation. Proposed artificial intelligence applications are limited to experimental receptor localisation, contraction analysis, and phenotyping.